神経調節市場：技術別（内部神経調節、外部神経調節）、用途別（慢性疼痛、尿失禁、片頭痛、腰痛、パーキンソン病、てんかん、振戦、うつ病、その他の用途）、生体材料別（金属生体材料、高分子生体材料、セラミック生体材料）：世界の機会分析および産業予測、2020-2030年

Neuromodulation Market By Technology (Internal Neuromodulation, External Neuromodulation), By Application (Chronic Pain, Urinary And Fecal Incontinence, Migraine, Failed Back Syndrome, Parkinson Disease, Epilepsy, Tremor, Depression, Other Applications), By Biomaterial (Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials), : Global Opportunity Analysis and Industry Forecast, 2020-2030

世界の神経調節市場は、2020年に24億8,020万ドルで、2021年から2030年にかけてCAGR6.2%を記録し、2030年には43億4,250万ドルに達すると予測されています。てんかん、アルツハイマー病、脳血管障害、パーキンソン... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年5月31日	US$5,769 シングルユーザーライセンスライセンス・価格情報注文方法はこちら	220	英語

サマリー

世界の神経調節市場は、2020年に24億8,020万ドルで、2021年から2030年にかけてCAGR6.2%を記録し、2030年には43億4,250万ドルに達すると予測されています。てんかん、アルツハイマー病、脳血管障害、パーキンソン病は、中枢および末梢神経系を侵す最も一般的な神経疾患です。これらの神経障害は、遺伝性疾患、先天性異常や障害、感染症、栄養失調を含む生活習慣や環境の健康問題、脳損傷、脊髄損傷、神経損傷によって引き起こされます。また、細菌、ウイルス、真菌による感染症も神経疾患の原因となります。
世界的に神経疾患の有病率が増加していることが、神経調節市場の成長を後押ししています。例えば、てんかん患者のための情報を提供する英国の慈善団体であるEpilepsy Action組織によると、2022年2月には、英国で約60万人がてんかんと診断されており、これは人口100人に1人の割合にあたります。また、老年人口の増加が、神経調節市場の成長を促進しています。また、製薬業界における研究開発活動の増加や、メーカーや研究者による神経調節デバイスの臨床試験数の増加も、市場の成長に寄与しています。さらに、神経調節デバイスの使用に関する認知度の高まりも、市場の成長を後押ししています。また、病院数の増加や医療インフラの整備も市場の成長に寄与しています。
また、神経調節装置の技術進歩の増加や、神経調節装置分野における製品発売の増加が、神経調節市場の成長に寄与しています。しかし、神経調節デバイスのコストが高いため、市場の成長は制限されると予想されます。
神経調節市場は、技術、用途、生体材料、地域に基づいて区分されます。技術別では、市場は主に内部神経調節と外部神経調節に分類されます。用途別では、慢性疼痛、尿・便失禁、片頭痛、故障性腰痛症候群、パーキンソン病、てんかん、振戦、うつ病、その他の用途に分類されます。生体材料に基づいて、それは、金属生体材料、高分子生体材料、およびセラミック生体材料に分類されます。地域別では、北米、ヨーロッパ、アジア太平洋、LAMEAで分析されます。
本レポートで紹介する主要企業は、Abbott、Aleva、Neurotherapeutics SA、Boston Scientific Corporation、LivaNova、Medtronic、MicroTransponder、Neuronetics、NeuroPace Inc、NeuroSigmaおよびNevro Corporationです。
ステークホルダーにとっての主なメリット
本レポートでは、差し迫った投資ポケットを解明するために、現在のトレンドと将来の予測とともに、世界の神経調節市場規模について詳細な分析を提供しています。
2021年から2030年までの市場分析を提供しており、利害関係者が市場に存在する機会を活用することを可能にすると期待されます。
地域の包括的な分析は、地域市場を理解し、戦略的な事業計画を促進し、優勢な機会を決定するのに役立ちます。
主要企業のプロファイルと成長戦略は、世界の神経調節市場の成長の競争的展望を理解するために徹底的に分析されています。

ページTOPに戻る

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: NEUROMODULATION MARKET, BY TECHNOLOGY
4.1 Overview
4.1.1 Market size and forecast
4.2 Internal Neuromodulation
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 External Neuromodulation
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: NEUROMODULATION MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Chronic Pain
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Urinary And Fecal Incontinence
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Migraine
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Failed Back Syndrome
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Parkinson Disease
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Epilepsy
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
5.8 Tremor
5.8.1 Key market trends, growth factors and opportunities
5.8.2 Market size and forecast, by region
5.8.3 Market analysis by country
5.9 Depression
5.9.1 Key market trends, growth factors and opportunities
5.9.2 Market size and forecast, by region
5.9.3 Market analysis by country
6.0 Other Applications
6.0.1 Key market trends, growth factors and opportunities
6.0.2 Market size and forecast, by region
6.0.3 Market analysis by country
CHAPTER 6: NEUROMODULATION MARKET, BY BIOMATERIAL
6.1 Overview
6.1.1 Market size and forecast
6.2 Metallic Biomaterials
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Polymeric Biomaterials
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Ceramic Biomaterials
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: NEUROMODULATION MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Technology
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by Biomaterial
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Technology
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by Biomaterial
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Technology
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by Biomaterial
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Technology
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by Biomaterial
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Technology
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by Biomaterial
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Technology
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by Biomaterial
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Technology
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by Biomaterial
7.3.5.3 United Kingdom
7.3.5.3.1 Market size and forecast, by Technology
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by Biomaterial
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Technology
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by Biomaterial
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Technology
7.3.5.5.2 Market size and forecast, by Application
7.3.5.5.3 Market size and forecast, by Biomaterial
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Technology
7.3.5.6.2 Market size and forecast, by Application
7.3.5.6.3 Market size and forecast, by Biomaterial
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Technology
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by Biomaterial
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by Technology
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by Biomaterial
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by Technology
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by Biomaterial
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Technology
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by Biomaterial
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Technology
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by Biomaterial
7.4.5.5 Rest of Asia-Pacific
7.4.5.5.1 Market size and forecast, by Technology
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by Biomaterial
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Technology
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by Biomaterial
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Technology
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by Biomaterial
7.5.5.2 Turkey
7.5.5.2.1 Market size and forecast, by Technology
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by Biomaterial
7.5.5.3 Saudi Arabia
7.5.5.3.1 Market size and forecast, by Technology
7.5.5.3.2 Market size and forecast, by Application
7.5.5.3.3 Market size and forecast, by Biomaterial
7.5.5.4 South Africa
7.5.5.4.1 Market size and forecast, by Technology
7.5.5.4.2 Market size and forecast, by Application
7.5.5.4.3 Market size and forecast, by Biomaterial
7.5.5.5 Rest of LAMEA
7.5.5.5.1 Market size and forecast, by Technology
7.5.5.5.2 Market size and forecast, by Application
7.5.5.5.3 Market size and forecast, by Biomaterial
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 LivaNova PLC
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Nevro Corporation
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Medtronic
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 NeuroSigma
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Neuronetics
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Bioventus Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 NeuroPace Inc
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 MicroTransponder
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 MicroTransponder
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Boston Scientific Corporation
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Abbott
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 2. NEUROMODULATION MARKET REVENUE, FOR INTERNAL NEUROMODULATION, BY REGION , 2020-2030,($MILLION)
TABLE 3. NEUROMODULATION MARKET INTERNAL NEUROMODULATION BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. NEUROMODULATION MARKET REVENUE, FOR EXTERNAL NEUROMODULATION, BY REGION , 2020-2030,($MILLION)
TABLE 5. NEUROMODULATION MARKET EXTERNAL NEUROMODULATION BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. GLOBAL NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 7. NEUROMODULATION MARKET REVENUE, FOR CHRONIC PAIN, BY REGION , 2020-2030,($MILLION)
TABLE 8. NEUROMODULATION MARKET CHRONIC PAIN BY COUNTRY, 2020-2030,($MILLION)
TABLE 9. NEUROMODULATION MARKET REVENUE, FOR URINARY AND FECAL INCONTINENCE, BY REGION , 2020-2030,($MILLION)
TABLE 10. NEUROMODULATION MARKET URINARY AND FECAL INCONTINENCE BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. NEUROMODULATION MARKET REVENUE, FOR MIGRAINE, BY REGION , 2020-2030,($MILLION)
TABLE 12. NEUROMODULATION MARKET MIGRAINE BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. NEUROMODULATION MARKET REVENUE, FOR FAILED BACK SYNDROME, BY REGION , 2020-2030,($MILLION)
TABLE 14. NEUROMODULATION MARKET FAILED BACK SYNDROME BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. NEUROMODULATION MARKET REVENUE, FOR PARKINSON DISEASE, BY REGION , 2020-2030,($MILLION)
TABLE 16. NEUROMODULATION MARKET PARKINSON DISEASE BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. NEUROMODULATION MARKET REVENUE, FOR EPILEPSY, BY REGION , 2020-2030,($MILLION)
TABLE 18. NEUROMODULATION MARKET EPILEPSY BY COUNTRY, 2020-2030,($MILLION)
TABLE 19. NEUROMODULATION MARKET REVENUE, FOR TREMOR, BY REGION , 2020-2030,($MILLION)
TABLE 20. NEUROMODULATION MARKET TREMOR BY COUNTRY, 2020-2030,($MILLION)
TABLE 21. NEUROMODULATION MARKET REVENUE, FOR DEPRESSION, BY REGION , 2020-2030,($MILLION)
TABLE 22. NEUROMODULATION MARKET DEPRESSION BY COUNTRY, 2020-2030,($MILLION)
TABLE 23. NEUROMODULATION MARKET REVENUE, FOR OTHER APPLICATIONS, BY REGION , 2020-2030,($MILLION)
TABLE 24. NEUROMODULATION MARKET OTHER APPLICATIONS BY COUNTRY, 2020-2030,($MILLION)
TABLE 25. GLOBAL NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
TABLE 26. NEUROMODULATION MARKET REVENUE, FOR METALLIC BIOMATERIALS, BY REGION , 2020-2030,($MILLION)
TABLE 27. NEUROMODULATION MARKET METALLIC BIOMATERIALS BY COUNTRY, 2020-2030,($MILLION)
TABLE 28. NEUROMODULATION MARKET REVENUE, FOR POLYMERIC BIOMATERIALS, BY REGION , 2020-2030,($MILLION)
TABLE 29. NEUROMODULATION MARKET POLYMERIC BIOMATERIALS BY COUNTRY, 2020-2030,($MILLION)
TABLE 30. NEUROMODULATION MARKET REVENUE, FOR CERAMIC BIOMATERIALS, BY REGION , 2020-2030,($MILLION)
TABLE 31. NEUROMODULATION MARKET CERAMIC BIOMATERIALS BY COUNTRY, 2020-2030,($MILLION)
TABLE 32. NEUROMODULATION MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 33. NORTH AMERICA NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 34. NORTH AMERICA NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 35. NORTH AMERICA NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
TABLE 36. NORTH AMERICA NEUROMODULATION MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 37. U.S. NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 38. U.S. NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 39. U.S. NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 40. CANADA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 41. CANADA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 42. CANADA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 43. MEXICO NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 44. MEXICO NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 45. MEXICO NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 46. EUROPE NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 47. EUROPE NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 48. EUROPE NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
TABLE 49. EUROPE NEUROMODULATION MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 50. GERMANY NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 51. GERMANY NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 52. GERMANY NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 53. FRANCE NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 54. FRANCE NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 55. FRANCE NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 56. UNITED KINGDOM NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 57. UNITED KINGDOM NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 58. UNITED KINGDOM NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 59. ITALY NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 60. ITALY NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 61. ITALY NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 62. SPAIN NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 63. SPAIN NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 64. SPAIN NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 65. REST OF EUROPE NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 66. REST OF EUROPE NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 67. REST OF EUROPE NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 68. ASIA-PACIFIC NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 69. ASIA-PACIFIC NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 70. ASIA-PACIFIC NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
TABLE 71. ASIA-PACIFIC NEUROMODULATION MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 72. CHINA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 73. CHINA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 74. CHINA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 75. JAPAN NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 76. JAPAN NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 77. JAPAN NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 78. INDIA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 79. INDIA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 80. INDIA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 81. AUSTRALIA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 82. AUSTRALIA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 83. AUSTRALIA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 84. REST OF ASIA-PACIFIC NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 85. REST OF ASIA-PACIFIC NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 86. REST OF ASIA-PACIFIC NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 87. LAMEA NEUROMODULATION MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 88. LAMEA NEUROMODULATION MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 89. LAMEA NEUROMODULATION MARKET, BY BIOMATERIAL, 2020-2030,($MILLION)
TABLE 90. LAMEA NEUROMODULATION MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 91. BRAZIL NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 92. BRAZIL NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 93. BRAZIL NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 94. TURKEY NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 95. TURKEY NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 96. TURKEY NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 97. SAUDI ARABIA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 98. SAUDI ARABIA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 99. SAUDI ARABIA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 100. SOUTH AFRICA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 101. SOUTH AFRICA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 102. SOUTH AFRICA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 103. REST OF LAMEA NEUROMODULATION MARKET BY TECHNOLOGY 2020-2030,($MILLION)
TABLE 104. REST OF LAMEA NEUROMODULATION MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 105. REST OF LAMEA NEUROMODULATION MARKET BY BIOMATERIAL 2020-2030,($MILLION)
TABLE 106.LIVANOVA PLC: COMPANY SNAPSHOT
TABLE 107.LIVANOVA PLC: OPERATING SEGMENTS
TABLE 108.LIVANOVA PLC: PRODUCT PORTFOLIO
TABLE 109.LIVANOVA PLC: NET SALES,
TABLE 110.LIVANOVA PLC: KEY STRATERGIES
TABLE 111.NEVRO CORPORATION: COMPANY SNAPSHOT
TABLE 112.NEVRO CORPORATION: OPERATING SEGMENTS
TABLE 113.NEVRO CORPORATION: PRODUCT PORTFOLIO
TABLE 114.NEVRO CORPORATION: NET SALES,
TABLE 115.NEVRO CORPORATION: KEY STRATERGIES
TABLE 116.MEDTRONIC: COMPANY SNAPSHOT
TABLE 117.MEDTRONIC: OPERATING SEGMENTS
TABLE 118.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 119.MEDTRONIC: NET SALES,
TABLE 120.MEDTRONIC: KEY STRATERGIES
TABLE 121.NEUROSIGMA: COMPANY SNAPSHOT
TABLE 122.NEUROSIGMA: OPERATING SEGMENTS
TABLE 123.NEUROSIGMA: PRODUCT PORTFOLIO
TABLE 124.NEUROSIGMA: NET SALES,
TABLE 125.NEUROSIGMA: KEY STRATERGIES
TABLE 126.NEURONETICS: COMPANY SNAPSHOT
TABLE 127.NEURONETICS: OPERATING SEGMENTS
TABLE 128.NEURONETICS: PRODUCT PORTFOLIO
TABLE 129.NEURONETICS: NET SALES,
TABLE 130.NEURONETICS: KEY STRATERGIES
TABLE 131.BIOVENTUS INC.: COMPANY SNAPSHOT
TABLE 132.BIOVENTUS INC.: OPERATING SEGMENTS
TABLE 133.BIOVENTUS INC.: PRODUCT PORTFOLIO
TABLE 134.BIOVENTUS INC.: NET SALES,
TABLE 135.BIOVENTUS INC.: KEY STRATERGIES
TABLE 136.NEUROPACE INC: COMPANY SNAPSHOT
TABLE 137.NEUROPACE INC: OPERATING SEGMENTS
TABLE 138.NEUROPACE INC: PRODUCT PORTFOLIO
TABLE 139.NEUROPACE INC: NET SALES,
TABLE 140.NEUROPACE INC: KEY STRATERGIES
TABLE 141.MICROTRANSPONDER: COMPANY SNAPSHOT
TABLE 142.MICROTRANSPONDER: OPERATING SEGMENTS
TABLE 143.MICROTRANSPONDER: PRODUCT PORTFOLIO
TABLE 144.MICROTRANSPONDER: NET SALES,
TABLE 145.MICROTRANSPONDER: KEY STRATERGIES
TABLE 146.MICROTRANSPONDER: COMPANY SNAPSHOT
TABLE 147.MICROTRANSPONDER: OPERATING SEGMENTS
TABLE 148.MICROTRANSPONDER: PRODUCT PORTFOLIO
TABLE 149.MICROTRANSPONDER: NET SALES,
TABLE 150.MICROTRANSPONDER: KEY STRATERGIES
TABLE 151.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
TABLE 152.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
TABLE 153.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
TABLE 154.BOSTON SCIENTIFIC CORPORATION: NET SALES,
TABLE 155.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
TABLE 156.ABBOTT: COMPANY SNAPSHOT
TABLE 157.ABBOTT: OPERATING SEGMENTS
TABLE 158.ABBOTT: PRODUCT PORTFOLIO
TABLE 159.ABBOTT: NET SALES,
TABLE 160.ABBOTT: KEY STRATERGIES

LIST OF FIGURES
FIGURE 1.NEUROMODULATION MARKET SEGMENTATION
FIGURE 2.NEUROMODULATION MARKET,2020-2030
FIGURE 3.NEUROMODULATION MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.NEUROMODULATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.NEUROMODULATION MARKET,BY TECHNOLOGY,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF INTERNAL NEUROMODULATION NEUROMODULATION MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF EXTERNAL NEUROMODULATION NEUROMODULATION MARKET,2020-2030(%)
FIGURE 14.NEUROMODULATION MARKET,BY APPLICATION,2020(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CHRONIC PAIN NEUROMODULATION MARKET,2020-2030(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF URINARY AND FECAL INCONTINENCE NEUROMODULATION MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MIGRAINE NEUROMODULATION MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF FAILED BACK SYNDROME NEUROMODULATION MARKET,2020-2030(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF PARKINSON DISEASE NEUROMODULATION MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF EPILEPSY NEUROMODULATION MARKET,2020-2030(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF TREMOR NEUROMODULATION MARKET,2020-2030(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DEPRESSION NEUROMODULATION MARKET,2020-2030(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHER APPLICATIONS NEUROMODULATION MARKET,2020-2030(%)
FIGURE 24.NEUROMODULATION MARKET,BY BIOMATERIAL,2020(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF METALLIC BIOMATERIALS NEUROMODULATION MARKET,2020-2030(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF POLYMERIC BIOMATERIALS NEUROMODULATION MARKET,2020-2030(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF CERAMIC BIOMATERIALS NEUROMODULATION MARKET,2020-2030(%)
FIGURE 28.NEUROMODULATION MARKET BY REGION,2020
FIGURE 29.U.S. NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 30.CANADA NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 31.MEXICO NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 32.GERMANY NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 33.FRANCE NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 34.UNITED KINGDOM NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 35.ITALY NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 36.SPAIN NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 37.REST OF EUROPE NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 38.CHINA NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 39.JAPAN NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 40.INDIA NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 41.AUSTRALIA NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 42.REST OF ASIA-PACIFIC NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 43.BRAZIL NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 44.TURKEY NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 45.SAUDI ARABIA NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 46.SOUTH AFRICA NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 47.REST OF LAMEA NEUROMODULATION MARKET,2020-2030($MILLION)
FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 52.COMPETITIVE DASHBOARD
FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 54.LIVANOVA PLC.: NET SALES ,($MILLION)
FIGURE 55.NEVRO CORPORATION.: NET SALES ,($MILLION)
FIGURE 56.MEDTRONIC.: NET SALES ,($MILLION)
FIGURE 57.NEUROSIGMA.: NET SALES ,($MILLION)
FIGURE 58.NEURONETICS.: NET SALES ,($MILLION)
FIGURE 59.BIOVENTUS INC..: NET SALES ,($MILLION)
FIGURE 60.NEUROPACE INC.: NET SALES ,($MILLION)
FIGURE 61.MICROTRANSPONDER.: NET SALES ,($MILLION)
FIGURE 62.MICROTRANSPONDER.: NET SALES ,($MILLION)
FIGURE 63.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
FIGURE 64.ABBOTT.: NET SALES ,($MILLION)

ページTOPに戻る

Table of Contents

Summary

The global neuromodulation market was valued at $2,480.2 million in 2020, and is projected to reach $4,342.5 million by 2030, registering a CAGR of 6.2% from 2021 to 2030. Epilepsy, Alzheimer disease, cerebrovascular diseases, and Parkinson's disease are the most common neurological disorder, which affect the central and peripheral nervous system. These neurological disorders are caused by genetic disorders, congenital abnormalities or disorders, infections, lifestyle or environmental health problems, including malnutrition, and brain injury, spinal cord injury or nerve injury. Bacterial, viral, and fungal infections also responsible for neurological disorders.
The increase in prevalence of neurological diseases globally drives the growth of the neuromodulation market. For instance, according to the Epilepsy Action organization, which is the British charity providing information for population with epilepsy, in February 2022, around 600,000 population are diagnosed with epilepsy, in UK, which is around one in every 100 population. In addition, increase in geriatric population propels the growth of neuromodulation market. The increase in R&D activities in the pharmaceutical sector and rise in number of clinical trials in the neuromodulation devices by manufacturers and researchers also contribute in the growth of market. Furthermore, surge in awareness for use of neuromodulation devices further boosts the market growth. The rise in number of hospitals and well-developed healthcare infrastructure further contributes in market growth.
In addition, increase in advancement in technology for neuromodulation devices and rise in product launch in the field of neuromodulation devices contribute in the growth of the neuromodulation market. However, the high cost of neuromodulation devices are expected to limit the growth of market.
The neuromodulation market is segmented on the basis of technology, application, biomaterial, and region. By technology, the market is mainly categorized into internal neuromodulation and external neuromodulation. By application, it is categorized in chronic pain, urinary and fecal incontinence, migraine, failed back syndrome, Parkinson disease, epilepsy, tremor, depression, and other applications. On the basis of biomaterial, it is divided into, metallic biomaterials, polymeric biomaterials, and ceramic biomaterials. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Abbott, Aleva, Neurotherapeutics SA., Boston Scientific Corporation, LivaNova, Medtronic, MicroTransponder, Neuronetics, NeuroPace Inc., NeuroSigma, and Nevro Corporation.
KEY BENEFITS FOR STAKEHOLDERS
The report provides an in-depth analysis of the global neuromodulation market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global neuromodulation market growth.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（高分子材料）の最新刊レポート

Allied Market Research社の高分子材料分野での最新刊レポート

本レポートと同じKEY WORD（migraine）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（高分子材料）の最新刊レポート

Allied Market Research社の高分子材料分野での最新刊レポート

本レポートと同じKEY WORD（migraine）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?